ATE83155T1 - Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke. - Google Patents

Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke.

Info

Publication number
ATE83155T1
ATE83155T1 AT88117833T AT88117833T ATE83155T1 AT E83155 T1 ATE83155 T1 AT E83155T1 AT 88117833 T AT88117833 T AT 88117833T AT 88117833 T AT88117833 T AT 88117833T AT E83155 T1 ATE83155 T1 AT E83155T1
Authority
AT
Austria
Prior art keywords
high ionic
plasma
protein formulations
recombination protein
ionic milieu
Prior art date
Application number
AT88117833T
Other languages
German (de)
English (en)
Inventor
Ted C K Lee
Michael E Hrinda
Original Assignee
Rhone Poulenc Rorer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22354487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE83155(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Int filed Critical Rhone Poulenc Rorer Int
Application granted granted Critical
Publication of ATE83155T1 publication Critical patent/ATE83155T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
AT88117833T 1987-10-29 1988-10-26 Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke. ATE83155T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11431487A 1987-10-29 1987-10-29
EP88117833A EP0314095B1 (en) 1987-10-29 1988-10-26 Plasma and recombinant protein formulation in high ionic strength media

Publications (1)

Publication Number Publication Date
ATE83155T1 true ATE83155T1 (de) 1992-12-15

Family

ID=22354487

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88117833T ATE83155T1 (de) 1987-10-29 1988-10-26 Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke.

Country Status (8)

Country Link
EP (1) EP0314095B1 (https=)
JP (1) JP2544968B2 (https=)
AT (1) ATE83155T1 (https=)
AU (1) AU622133B2 (https=)
CA (1) CA1329760C (https=)
DE (1) DE3876600T2 (https=)
ES (1) ES2053676T3 (https=)
GR (1) GR3006506T3 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0410207B1 (en) * 1989-07-24 1997-01-22 Bayer Corporation Stabilization of highly purified proteins
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
WO1993022336A1 (en) * 1992-04-30 1993-11-11 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor viii complex
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US5514781A (en) * 1994-04-11 1996-05-07 Bayer Corporation Use of azoles as virucidal agents in solutions of biologically active proteins
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
US7253262B2 (en) 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244824B2 (en) 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CZ298429B6 (cs) * 1997-04-28 2007-10-03 Eli Lilly And Company Stabilní lyofilizovaný prostredek
EP1561469A1 (en) * 1997-04-28 2005-08-10 Eli Lilly & Company Activated Protein C Formulations
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
PT917879E (pt) * 1997-11-22 2002-12-31 Roche Diagnostics Gmbh Processo melhorado para estabilizacao de proteinas
DK1820516T3 (da) 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2001262939A1 (en) 2000-05-24 2001-12-03 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
CN1671410B (zh) 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
CN1703233A (zh) * 2002-07-12 2005-11-30 米德列斯公司 防止蛋白氧化降解的方法和组合物
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
EP1685160A1 (en) * 2003-11-10 2006-08-02 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation
CN1917861B (zh) 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
CA2683317C (en) * 2007-04-26 2014-12-16 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
MX339060B (es) 2008-11-07 2016-05-09 Baxter Int Formulaciones del factor viii.
CA2821945A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Aqueous factor viii solution
CN107233569B (zh) 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 抗体制剂和方法
US20160000884A1 (en) * 2012-08-13 2016-01-07 Novo Nordisk A/S Liquid Factor VIII Formulations
WO2017076967A1 (en) * 2015-11-05 2017-05-11 Novo Nordisk A/S Fviii formulation
JP7110360B2 (ja) 2017-10-09 2022-08-01 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥方法
CN113597532B (zh) 2019-03-14 2023-02-17 泰尔茂比司特生物技术有限公司 冻干容器填充固定装置、系统及使用方法
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
JP2025512143A (ja) 2020-11-09 2025-04-17 武田薬品工業株式会社 酸化ケイ素吸着を使用する血漿からのｆｖｉｉｉの精製

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237512A1 (de) * 1982-10-09 1984-04-12 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
DE3609431A1 (de) * 1986-03-20 1987-09-24 Biotest Pharma Gmbh Verfahren zur herstellung eines den blutgerinnungsfaktor viii enthaltenden, sterilen praeparates

Also Published As

Publication number Publication date
EP0314095B1 (en) 1992-12-09
CA1329760C (en) 1994-05-24
DE3876600T2 (de) 1993-04-15
DE3876600D1 (de) 1993-01-21
ES2053676T3 (es) 1994-08-01
AU2452088A (en) 1989-05-04
JP2544968B2 (ja) 1996-10-16
EP0314095A1 (en) 1989-05-03
AU622133B2 (en) 1992-04-02
JPH01149733A (ja) 1989-06-12
GR3006506T3 (https=) 1993-06-30

Similar Documents

Publication Publication Date Title
ATE83155T1 (de) Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke.
ATE76304T1 (de) Plasma- und rekombinationsproteinformulierungen in einem milieu niedriger ionenstaerke.
ATE198143T1 (de) Zahnpasten
FI873364A0 (fi) Foerfarande foer framstaellning av ett sytotoxiskt laekemedel.
DE69519580D1 (de) Zahnpflegemitteln
DK183386A (da) Sucralfatsuspension
DK0700380T3 (da) N-Alkylthiopolyaminderivater som radioprotektive midler
MX9301450A (es) Recipiente con gases comprimidos para la utilizacion de polioxietilen-gliceril-oleatos
DK0378262T3 (da) Flydende detergentsammensætning indeholdende et enzym og et enzymstabiliseringssystem
NO921256D0 (no) Aminosyre-beta-lyaseenzyminhibitor som deodoranter
FI972384L (fi) Uudet dipeptidiset p-amidinobentsyyliamidit, jotka sisältävät N-terminaalisia sulfonyyli- tai amidinosulfonyyliryhmiä
DE3578516D1 (de) Haarwaschmittelzusammensetzung.
DE69432899D1 (de) Flüssige ionische Zusammensetzungen verwendende Ionenpunktquellen hoher Luminosität
BR8901275A (pt) Composicao detergente aquosa,abrasiva,homogenea,despejavel
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
IT213814Z2 (it) Sega meccanica da traforo.
IT8821454V0 (it) Sega meccanica da traforo.
NO901452D0 (no) Blandinger inneholdende 2-tiocyano-metyltio-benzotiazol for anvendelse som industrielle mikrobiocider.
DK78788D0 (da) 4-substituerede benzamid-derivater og farmaceutiske midler indeholdende saadanne derivater
AU2817589A (en) Amino anthracenediones-bis platinum complexes, useful as antitumoral agents
BG40952A3 (en) Herbicide means
FI935342A0 (fi) Menetelmä stabiilisuudeltaan parempien natriumperkarbonaattipartikkelien valmistamiseksi
AU580890B2 (en) P-acylaminobenzamides
ATE90195T1 (de) Minoxidil-gel.
IT1175939B (it) Stabilizzatore di fascio luiminoso

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time